Revolution Medicines, Inc.
RVMD
$37.01
$0.531.45%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -97.16% | -97.49% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -97.16% | -97.49% |
Cost of Revenue | 50.55% | 50.92% | 46.66% | 67.35% | 76.80% |
Gross Profit | -50.85% | -52.81% | -52.15% | -86.54% | -104.97% |
SG&A Expenses | 62.33% | 52.02% | 55.95% | 60.54% | 59.95% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 55.82% | 48.40% | 45.70% | 59.07% | 63.76% |
Operating Income | -56.02% | -49.69% | -49.35% | -70.15% | -78.54% |
Income Before Tax | -55.49% | -43.15% | -36.59% | -69.00% | -76.21% |
Income Tax Expenses | 78.63% | 78.63% | 78.63% | 108.60% | -739.05% |
Earnings from Continuing Operations | -56.40% | -44.03% | -37.52% | -71.14% | -75.27% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -56.40% | -44.03% | -37.52% | -71.14% | -75.27% |
EBIT | -56.02% | -49.69% | -49.35% | -70.15% | -78.54% |
EBITDA | -56.41% | -49.94% | -49.56% | -70.71% | -79.27% |
EPS Basic | -23.49% | -6.30% | 5.49% | -10.04% | -16.27% |
Normalized Basic EPS | -28.83% | -10.76% | 1.52% | -3.26% | -11.39% |
EPS Diluted | -23.49% | -6.30% | 5.49% | -10.04% | -16.27% |
Normalized Diluted EPS | -28.83% | -10.76% | 1.52% | -3.26% | -11.39% |
Average Basic Shares Outstanding | 23.62% | 32.92% | 48.29% | 59.43% | 54.51% |
Average Diluted Shares Outstanding | 23.62% | 32.92% | 48.29% | 59.43% | 54.51% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |